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Summary.-A hypothesis that m-AMSA may have greater cytotoxicity in melanin-
containing tumour tissues, because it may reversibly bind to melanin, leading to
prolonged drug exposure, was examined. Clonal lines of B16 melanoma which
differed widely in pigmentation level were selected by isolating artificial lung
colonies and in vitro soft-agar colonies, and implanting them into mice. Excision
cell-survival assays performed 24 h after drug administration showed that in vivo
sensitivity to m-AMSA progressively i creased as pigmentation level decreased,
but that m-AMSA drug levels measured 24 h after treatment were much lower in
amelanotic than in melanotic lines. In dose-survival studies the reduced sensitivity
of melanotic cell lines was revealed as a large shoulder (Dq=27 mg/kg) though the
terminal slopes for melanotic and amelanotic cell lines were similar (D1o- 31 mg/kg).
Time-course studies indicated that there was no significant loss of drug from a
melanotic cell line for 72 h after drug administration, though in an amelanotic cell
line drug levels fell 10-fold in 10 h. There was, however, no evidence for prolonged
drug cytotoxicity in the melanotic cell line.
Using a fractionated drug-treatment regime, the greater cytotoxicity of m-AMSA
to amelanotic tumour tissue was confirmed in a non-invasive regrowth-delay assay.
m-AMSA (4'-(9'-acridinylamino)meth-
anesulphon-m-anisidide) is a new cyto-
toxic drug which was discovered in the
early 1970s (Cain et al., 1974), was
subsequently shown to be active in a wide
spectrum of animal tumours (Rosenweig
et al., 1979) and is now undergoing
Phase II clinical trials under the auspices
of the NCI (Issell, 1980). In animal tests
the agent was unexpectedly effective
against B16 melanoma (Cain & Atwell,
1974), a tumour which is generally
insensitive to chemotherapy, except for a
few alkylating agents (Skipper, 1976).
Pharmacological studies (Shoemaker et
al., 1978) using 14C-labelled m-AMSA
showed that the agent binds strongly to
B16 melanoma cell nuclei, which is
compatible with its proposed mechanism
of action as a DNA intercalating agent
(Gormley et al., 1978; Johnson et al.,
1976). However, there was also substantial
binding to other subcellular organelles,
including melanosomes, and it was sug-
gested by Shoemaker et al. (1978) that
retention of m-AMSA in a stable, yet
reversible, association with melanin, lead-
ing to prolonged drug exposure, might
explain the high in vivo activity against
B16 melanoma.
In this study we have examined the
relationship between m-AMSA cytotox-
icity andthe level ofmelanin pigmentation
of B16 melanoma cells, by selecting clonal
variants with differingpigmentationlevels,
and testing their in vivo sensitivity to
m-AMSA in an in vitro cell-survival assay.
METHODS
Mice and tumours.-Uncloned samples of
B16 melanoma and Lewis lung carcinoma
were maintained in C57BL/Cbi mice by i.m.
implantation of tumour brei (Steel & Adams,T. C. STEPHENS AND J. H. PECAOCK
1975). The uncloned B16 melanoma used in
this study was highly pigmented.
Drug treatment.-m-AMSA methanesulpho-
nate was synthesized in the laboratory of the
late Dr B. Cain, and supplied to us by Dr
P. B. Roberts.
For in vivo treatments, the drug was
dissolved in DMSO at 20 or 40 mg/ml and
then diluted 10-fold with 50o Tween 80 in
Dulbecco's phosphate-buffered saline "A"
(PBSA) just before i.p. injection.
For in vitro treatments the drug wvas
initially dissolved as described above. It was
then serially diluted with Ham's F12 culture
medium to 50 jug/ml, which was added
directly to suspension cultures to give final
drug doses up to 3 ,ug/ml. The technique to
maintain gassed and stirred suspension
cultures has been described by Stephens et al.
(1980).
In vitro tumour-cell survival assays.-The
disaggregation procedure using trypsin to
obtain single-cell suspensions from B16
melanoma and Lewis lung carcinoma, and the
technique of plating cells in vitro in soft agar
to measure clonogenic tumour-cell survival,
have been described previously (Courtenay,
1976; Stephens et al., 1978; Stephens &
Peacock, 1978). In this study, uncloned B16
melanoma gave a mean tumour cell yield of
1-2 x 108 cells/g and a mean plating efficiency
(PE) of 60%, and uncloned Lewis lung
carcinoma yielded 8 x 107 tumour cells/g with
a mean PE of 58%.
The effectiveness of in vivo drug treatment
was expressed as the surviving fraction per
tumour, which was determined as: (weight of
treated tumour x treated tumour-cell yield
per g x treated tumour PE) . (weight of
untreated tumour x untreated tumour-cell
yield per g x untreated tumour PE). Cell
killing in vitro was expressed as surviving
fraction (SF =PE treated - PE untreated).
Selection of clonal variants of B16 melan-
oma.-Clonal variants of B16 melanoma with
different levels of pigmentation were derived
in two ways: by selecting lung colonies in vivo
and by selecting in vitro colonies in soft-agar.
Twenty thousand trypsinized B16 melanoma
cells together with 106 15-um-diameter
plastic microspheres (3M) were injected i.v.
into mice via the tail vein. Twenty-one days
later about 0-3% of the injected cells had
formed discrete macroscopic colonies in the
lung (Hill & Stanley, 1975). Although most
of the lung colonies were highly pigmented,
as was the uncloned parent tumour, 5-10%
were only weakly pigmented. Several colonies
of widely differing pigmentation level were
dissected out and implanted s.c. into fresh
mice, using a trocar. Two weeks later each
s.c. implant had grown to beyond 0 5 g; they
were all dissected out and the tumours with
the highest and lowest levels of pigmentation
(determined by macroscopic appearance)
were given the designations Al (amelanotic)
and A2 (melanotic) and transplanted i.m. as
tumour brei for experiments. A second clonal
selection was performed using the same
technique and on this occasion clonal lines of
low, intermediate and high pigmentation
level were selected and designated Bi to BI1.
Bl, B2 and BlO did not grow well and were
discarded; the other lines were transplanted
i.m. for experiments.
Clonal variants were selected in vitro by
carefully picking B16 cell colonies from agar
culture dishes with a fine Pasteur pipette.
The colonies were derived by plating un-
treated cells from clonal lines Al and A2.
Colonies of widely differing pigmentation
level were chosen and implanted s.c. into
recipient mice by trocar. When the s.c.
implants had grown to over 0 5 g, they were
transplanted i.m. as a tumour brei for
experiments. The clones were designated
DI-7.
Measurement of mn-AMSA in tumour tissue.
-Weighed samples of tumour (0-3-0-6 g)
xvere digested for 24 h at 75°C with 0 5 ml of
2N NaOH. m-AMSA was then extracted and
measured using a fluorescence technique as
described by Gormley & Cysyk (1979).
Assessment of tumour pigmentation.-The
levels of pigmentation of clonally derived
lines of B16 melanoma were determined
qualitatively bytheir macroscopic appearance
and quantitatively by artificial lung colony
formation. It was noticed that there was a
good correlation between the macroscopic
appearance of cloned B16 tumours and the
proportions of highly melanotic (black),
slightly melanotic (grey) and amelanotic
(white) lung colonies produced when trypsin-
ized cell suspensions were injected i.v.
Amelanotic tumours yielded mostly amel-
anotic lung colonies; highly melanotic tu-
mours yielded only melanotic lung colonies;
and tumours of intermediate pigmentation
gave a mixture of amelanotic, lightly pig-
mented and highly melanotic lung colonies.
However, it was important to perform
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differential counts of colonies on freshly
dissected lungs, since fixation of the tissue in
either formol-saline or Bouin's fluid led to
bleaching of slightly melanotic colonies.
Measurement of regrowth delay.-I.m. tu-
mours were measured 3 x per week, by
passing unshaved legs through a series of
calibrated holes in a perspex disc. This
measure was related to tumour weight by a
calibration curve (Steel & Adams, 1975).
Regrowth delay was determined as the time
displacement between untreated and treated
median growth curves at a tumour size
of 05g.
RESULTS
Cell-survival response of uncloned B16
melanoma and Lewis lung carcinoma to
m-AMSA
Tumour-cell survival was measured by
excision assay 24 h after administration
of m-AMSA to mice bearing either un-
cloned B16 melanoma or Lewis lung
carcinoma. Fig. I shows the response of
0-25 g i.m. tumours to drug doses up to
about the LD10 of 30 mg/kg. B16 melan-
oma was much less sensitive to m-AMSA
than Lewis lung carcinoma. In the former
case the cell-survival curve shows a large
shoulder, and the maximum slope has not
been reached at LD10 drug levels, whereas
in the latter there is only a small shoulder,
followed by an exponential decrease in
survival with a D1o (dose to decrease cell
survival by 90%0) of - 16 mg/kg. By
analogy with a radiation survival curve,
the shoulder on the Lewis lung curve may
be expressed as a Dq (dose at which
extrapolated exponential survival curve
reaches unity) of about 4 mg/kg.
Cell-survival response of B16 melanoma
clonal lines A1 and A2 to m-AMSA
B16 melanoma clonal lines Al (amelan-
otic) and A2 (melanotic) were treated in
vivo with m-AMSA, and tumour-cell
survival was measured after tumour ex-
cision 24 h later. Theresults ofexperiments
performed with passages 1, 2, 3, 5, 7 and 8,
after clonal selection from lung colonies,
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FIG. 1. Cell-survival curves for uncloned B16
melanoma (0) and Lewis lung carcinoma
(0) following in vivo treatment with m-
AMSA. Mice bearing 0.25g tumours were
treated i.p. with m-AMSA and 24 h later
tumours were excised, disaggregated and
cell survival measured in vitro.
are shown in Fig. 2. In each passage the
amelanotic line Al (open symbols) was
more sensitive to m-AMSA than the
melanotic line A2 (closed symbols). The
cell-survival response of clone Al was
exponential, with a D1o of 31 mg/kg and
no apparent shoulder. Clone A2 exhibited
a large shoulder (Dq = 27 mg/kg) followed
by an exponential decrease in cell survival
with the same D1o as for clone Al. When
amelanotic clone Al and melanotic clone
A2 were grown in different legs of the
same mouse, they still showed different
sensitivities to m-AMSA (open and closed
triangles respectively in Fig. 2). The
Table shows no significant differences in
the growth rate (estimated as time to
grow to treatment size), trypsinization
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exposed for 1 h in stirred suspension
cultures to m-AMSA at a range of doses.
The cells were then collected by centrifu-
gation, diluted, and plated in soft agar for
cell-survival assessment. Fig. 3 shows
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FIG. 2.-Cell-survival curves of B16 melan-
oma clones Al (amelanotic, 0, A) and A2 C
(melanotic, *, *) after in vivo treatment
with m-AMSA. Treatment and assay L
details as for Fig. 1. Data for the clones
growing in separate mice (@0) and both
tumours growing in separate legs of the
same mouse (AA) are shown.
efficiency or cloning efficiency, of un-
treated tumours, which could account for
the differential response of clonal lines Al
and A2 to m-AMSA. The only obvious
difference was their melanin content.
In vitro sensitivity of cells from B16
melanoma clones Al and A2
Trypsinized cell suspensions derived
from tumour clones Al and A2 were
-2
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FIG. 3.-In vitro cell-survival curves obtained
by treating disaggregated suspensions of
B16 melanoma cells from clones Al and A2
with m-AMSA, for 1 h in stirred suspension.
TABLE.-Growth and survivalparameters of 14 untreated tumoursfrom clones Aland A2*
Pigmentation
levelt
Size at time of
treatment (g)
Al low 0-24+0-09
A2 high 0-22+0-08
* Determined in passages 1 to 8.
t Macroscopic appearance.
t 8 days after implantation.
P.E.
Cell yield ( x 107) g (%)
9-3+3-6 64+ 16
9-4+4*4 68+ 13
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FIG. 4.-Relationship between tumour-cell
survival (SF) after in vivo treatment (top
panel), residual m-AMSA level in tumour
24 h after treatment (bottom panel) and
level of tumour pigmentation (middle
panel), for a range of B16 melanoma
clones selected as lung colonies. Pigmenta-
tion level was assessed as the proportions
of amelanotic (0), poorly pigmented (O)
and highly melanotic (0) lung colonies
produced when cell suspensions were
injected into recipient mice via the tail
vein. Clones are arranged in order of
increasing pigmentation.
that over the dose range studied tumour-
cell survival was similar for each of the
clonal lines, and was consistent with a
response curve of progressively increasing
slope.
D-CLONE DES IGNATION
FIG. 5.-Relationship between tumour-cell
survival (top panel), residual m-AMSA
level in tumour at 24 h (bottom panel) and
tumour pigmentation level, for a range of
B16 melanoma clones selected as in vitro
soft-agar colonies. Other details in Fig. 4.
Correlation between melanin pigmentation
level, cell survival to m-AMSA and drug
levels in B16 melanoma clones B and D
New B16 melanoma clonal lines were
selected as lung colonies and soft-agar
colonies and designated as B3 to 9 and
DI to 7 respectively. I.m. transplants of
each of the clonal lines were ranked for
their melanin content by their macro-
scopic appearance and by performing
lung-cloning assays, and counting pro-
portions of white (amelanotic), grey
(lightly pigmented) and black (highly
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melanotic) colonies. The middle panels of
Figs 4 & 5 show the clonal structure of B
and D clones, respectively. They are
ranked in order of increasing pigmenta-
tion. It is clear that clones B5 and D2
were the least pigmented, producing over
900o white lung colonies, whilst clones B9,
D4, D5 and D6 were very highly pig-
mented, producing over 950o black lung
colonies. The other clonal lines were
intermediate, and appeared macroscopi-
cally as shades of grey.
The upper panels in Figs 4 and 5 show
the extent oftumour-cell killing 24 h after
administration of 40 mg/kg m-AMSA.
Amelanotic tumours were most sensitive,
and there was a progressive decrease in
sensitivity with increasing levels of pig-
mentation. However, drug levelsintumour
tissue measured 24 h after treatment were
over 10 x higher in highly pigmented
tumours (lower panels, Figs 4 and 5) than
in amelanotic tumours. Thus, drug con-
centration in tumour tissue at 24 h
appeared to be inversely related to the
extent of tumour-cell killing at that time,
an unexpected finding.
Time-course oftumour-cell killing, and drug
levels, in B16 melanoma clonal lines D2
and D4
Clonal lines D2 (amelanotic) and D4
(highly melanotic) were chosen for this
study because they showed no significant
tendency to drift towards an intermediate
pigmentation level when repeatedly trans-
planted. This drift was encountered with
clonal lines Al and A2, and B5 and B9.
Mice bearing tumours D2 and D4 were
treated with m-AMSA at a dose of
40 mg/kg, and at various times up to 3
days later the animals were killed, their
tumours excised, and assayed for cell
survival and drug levels (Fig. 6). Drug
levels remained high for the duration of
the experiment in the highly melanotic
line, but fell 10-fold over the first 10 h in
the amelanotic line.
With both clonal lines, cell survival
decreased to a minimum during the first
20 h but then recovered during the next
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FIG. 6. Time course of tumour-cell killing
(upper panel) and m-AMSA levels in
tumour (lower panel) for B16 melanoma
clones D2 (amelanotic, 0) and D4 (mel-
anotic, 0).
2 days with a doubling time (TD) of 23-5 h.
This recovery rate is consistent with
repopulation by surviving tumour cells.
However, the maximum extent of cell
killing was much greater with the amelan-
otic line D2 than with the melanotic
line D4.
Regrowth delay in B16 melanoma clonal
lines D2 and D4
Experiments were performed to deter-
mine whether m-AMSA would produce a
differential regrowth delay between melan-
otic and amelanotic tumours, as would be
expected from the cell-survival studies.
Our previous experience with B16 melan-
oma indicated that the cell killing in
macroscopic tumours produced by a
maximum tolerated single dose of drug
1- _
826
1CLONAL VARIATION IN MELANOMA DRUG SENSITIVITY
-A 0 A
/o'
/ / ,' A,
0/
0 0
0 5 10 15 20
B
. A/
a A/
I
A/
4 1 i 4 4 4 I
0 5 10 15 20
TIME AFTER IMPLANTATION (days)
FIG. 7. Regrowth delay induced by fractionated treatment of B16 melanoma clones D2 (panel A)
and D4 (panel B) with m-AMSA. Fractionated doses of 3 mg/kg (AA) and 6 mg/kg (l O ) given
at the times indicated by arrows ( .1 ) are compared with untreated controls ( 0).
would be insufficient to produce a measur-
able regrowth delay. Therefore, m-AMSA
was administered in daily fractions, start-
ing 3 days after i.m. tumour implantation.
Fig. 7 shows the responses of clonal lines
D2 and D4, treated with repeated doses
of 3 or 6 mg/kg m-AMSA. Although there
were measurable regrowth delays of 2-5
and 5 days, after 3 and 6 mg/kg respec-
tively, in the amelanotic clone D2 (panel
A), no significant responses were seen with
the melanotic clone D4.
DISCUSSION
We have demonstrated a clear negative
correlation between melanin content and
sensitivity to m-AMSA in cloned lines of
B16 melanoma. This conflicts with the
conclusions of Shoemaker et al. (1978)
that the apparently high activity of
m-AMSA against B16 melanoma may be
due to a reversible binding of the drug to
melanin granules, followed by a gradual
release, leading to a prolonged period of
exposure to the agent and hence greater
cytotoxicity. Our time-course data for a
highly melanotic clone of B16 melanoma
(see Fig. 6) indicates that loss of drug
does not occur during the 3 days imme-
diately after drug administration. Further-
more, the repopulation of highly pig-
meted tumours by surviving cells is not
apparently delayed, relative to non-
pigmented tumours, and it would seem
that m-AMSA which is bound by highly
pigmented tissue is no longer cytotoxic.
From the results presented in Fig. 2 we
conclude that highly pigmented B16
melanoma tissues have a finite drug-
binding capacity, and when this is satis-
fied, cells express a sensitivity to additional
drug (expressed as survival-curve slope)
which is the same as the sensitivity of
unpigmented B16 cells. After in vitro
exposure to m-AMSA, however, highly
pigmented and unpigmented B16 melan-
oma cell lines showed similar sensitivity
(Fig. 3) which seems to contradict the
above hypothesis. However, the failure to
observe differential cytotoxicity in vitro
could be related to the experimental
procedure. Cells were exposed to drug for
only 1 h and, in order to achieve measur-
able cell killing, high doses were used.
In this situation it is possible that intra-
cellular binding of m-AMSA by melanotic
cells was insufficient significantly to reduce
the availability of free active drug. In vivo
a significant extent of m-AMSA inactiva-
tion in highly pigmented tumours may
occur due to the binding of drug by
extracellular melanin released when tu-
mour cells die in regions of necrosis,
which account for up to 350o of a tumour's
volume (Stephens & Peacock, 1978). Our
measurements ofm-AMSAlevelsin tumour
tissue did not distinguish between un-
bound, intra- or extra-cellularly botund
drug.
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FIG. 8.-Sensitivity of wild type B16 melan-
oma and Lewis lung carcinoma (LL) to a
range of cytotoxic drugs at LD1o doses.
Agents were administered to tumour-
bearing mice and 24 h later excision cell-
survival assays were performed. Data
were collected over 5 years. * Extrapolated
values.
The results presented in Fig. 1, which
show that our Lewis lung tumour is more
sensitive to m-AMSA than our wild-type
B16 melanoma, are consistent with results
that we and others (Skipper, 1976) have
observed for many cytotoxic agents in
these tumour systems. Fig. 8 shows the
comparative sensitivities in terms of cell
survival for the two tumours treated in
vivo with a wide range of drugs as single
LD10 doses. In many cases, Lewis lung
tumour (LL) is more sensitive than B16,
and we had supposed that this may often
reflect the slightly faster growth rate of
the former. The doubled sensitivity of LL
to m-AMSA over the amelanotic B16
melanoma may be due to this difference.
However, the possibility that melanin
binding may reduce the effectiveness of
drugs other than m-AMSA, cannot be
overlooked. Although preliminary studies
indicate that the pigmentation level of
B16 melanoma is not an important factor
in cell killing by melphalan or methyl-
CCNU, we have some evidence for greater
cell killing by cyclophosphamide and
DTIC in unpigmented clones of B16
melanoma. It may be relevant that
wild-type B16 melanoma and LL carci-
noma have similar responses to melphalan
and methyl-CCNU, but LL is much more
sensitive than B16 melanoma to cyclo-
phosphamide (Fig. 8).
We propose in future to explore further
the possibility that melanin, and perhaps
some other cell products, are significant
determinants of the sensitivity of tumour
cells to some cytotoxic drugs.
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